Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low intensity bridging may be best path to CAR T in adult ALL

Publish date:: June 1, 2019

Key clinical point: A high-intensity chemotherapy bridging strategy increased the risk of infection before treatment with a CD19 CAR T-cell therapy in adults with relapsed/refractory acute lymphoblastic leukemia.

Major finding: The high intensity bridging regimens were associated with a higher rate of grade 3 or 4 infections – 15 versus 11 infections (Fisher’s P = .002).
Study details: A retrospective analysis of a previous study looking at 53 adults with relapsed/refractory ALL.

Disclosures: Dr. Perica reported royalties from technology licensed to Neximmune. The original study was funded by several foundations and Juno Therapeutics.

Citation:

Perica K et al. ASCO 2019, Abstract 2520.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,